<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template"><id>486fd439-68bf-4f9a-bd28-795ee7294867</id><name>NSTEMI with possible PCI reperfusion Order Group</name><description><lifecycle_state>Initial</lifecycle_state><details><purpose/><use/><misuse/></details><other_details><item><key>MetaDataSet:Sample Set </key><value>Template metadata sample set </value></item><item><key>Acknowledgements</key><value/></item><item><key>Business Process Level</key><value/></item><item><key>Care setting</key><value/></item><item><key>Client group</key><value/></item><item><key>Clinical Record Element</key><value/></item><item><key>Copyright</key><value/></item><item><key>Issues</key><value/></item><item><key>Owner</key><value/></item><item><key>Sign off</key><value/></item><item><key>Speciality</key><value/></item><item><key>User roles</key><value/></item></other_details></description><annotations path="[openEHR-EHR-SECTION.adhoc.v1]"><items><item><key>Technical.ï»© Technical Traceability</key><value>{~AHSID~486fd439-68bf-4f9a-bd28-795ee7294867~NAME~NSTEMI with possible PCI reperfusion Order Group}</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]"><items><item><key>CKT.Clinical Guidance</key><value>&lt;p&gt;Administer Ticagrelor or Clopidogrel IN ADDITION TO acetylsalicylic acid (ASA) to patients with high suspicion of NSTE-ACS in the absence of an excessive risk of bleeding:. &amp;nbsp;Then choose fondaparinux or enoxparin.&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Ticagrelor OR Clopidogrel&apos;]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;ticagrelor (BRILINTA) 180 mg PO loading dose followed by 90 mg PO BID (preferred unless patient has history of intracerebral hemorrhage)&apos;]/items[openEHR-EHR-SECTION.clinical_guidance.v1]"><items><item><key>CKT.Clinical Guidance</key><value>&lt;p&gt;When given in combination with ticagrelor (BRILINTA), max recommended aspirin dose is 100 mg po daily.&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Ticagrelor OR Clopidogrel&apos;]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;ticagrelor (BRILINTA) 180 mg PO loading dose followed by 90 mg PO BID (preferred unless patient has history of intracerebral hemorrhage)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;ticagrelor tablet; 180 mg, oral, once&apos;]/activities[at0001]"><items><item><key>CKT.Content Details</key><value>&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;This is a restricted drug. What is the indication for this order? &lt;strong&gt;Drug is prescribed in combination with low dose ASA in patient with Acute Coronary Syndrome&lt;/strong&gt;&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Ticagrelor OR Clopidogrel&apos;]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;ticagrelor (BRILINTA) 180 mg PO loading dose followed by 90 mg PO BID (preferred unless patient has history of intracerebral hemorrhage)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;ticagrelor tablet; 180 mg, oral, once&apos;]/activities[at0156]"><items><item><key>Transform.Preselected</key><value>&lt;p&gt;Y&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Ticagrelor OR Clopidogrel&apos;]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;ticagrelor (BRILINTA) 180 mg PO loading dose followed by 90 mg PO BID (preferred unless patient has history of intracerebral hemorrhage)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;ticagrelor tablet; 90 mg, oral, 2 times per day, First dose tomorrow&apos;]/activities[at0001]"><items><item><key>Transform.Technical Notes</key><value>&lt;p&gt;Starting S+1&lt;/p&gt;</value></item><item><key>CKT.Content Details</key><value>&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;This is a restricted drug. What is the indication for this order?&amp;nbsp;&lt;strong&gt;Drug is prescribed in combination with low dose ASA in patient with Acute Coronary Syndrome&lt;/strong&gt;&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Ticagrelor OR Clopidogrel&apos;]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;ticagrelor (BRILINTA) 180 mg PO loading dose followed by 90 mg PO BID (preferred unless patient has history of intracerebral hemorrhage)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;ticagrelor tablet; 90 mg, oral, 2 times per day, First dose tomorrow&apos;]/activities[at0156]"><items><item><key>Transform.Preselected</key><value>&lt;p&gt;Y&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Ticagrelor OR Clopidogrel&apos;]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;clopidogrel (PLAVIX) 300 mg loading dose followed by 75 mg daily (select if ticagrelor cannot be used or if oral anticoagulation is also being used)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;clopidogrel tablet; 300 mg, oral, once&apos;]/activities[at0156]"><items><item><key>Transform.Preselected</key><value>&lt;p&gt;Y&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Ticagrelor OR Clopidogrel&apos;]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;clopidogrel (PLAVIX) 300 mg loading dose followed by 75 mg daily (select if ticagrelor cannot be used or if oral anticoagulation is also being used)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;clopidogrel tablet; 75 mg, oral, daily, First dose tomorrow&apos;]/activities[at0001]"><items><item><key>Transform.Technical Notes</key><value>&lt;p&gt;Starding S+1&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Ticagrelor OR Clopidogrel&apos;]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;clopidogrel (PLAVIX) 300 mg loading dose followed by 75 mg daily (select if ticagrelor cannot be used or if oral anticoagulation is also being used)&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;clopidogrel tablet; 75 mg, oral, daily, First dose tomorrow&apos;]/activities[at0156]"><items><item><key>Transform.Preselected</key><value>&lt;p&gt;Y&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Fondaparinux OR Enoxaparin OR Heparin&apos;]/items[openEHR-EHR-SECTION.clinical_guidance.v1 and name/value=&apos;Clinical Guidance&apos;]"><items><item><key>CKT.Clinical Guidance</key><value>&lt;p&gt;Fondaparinux in contraindicated if CrCl is less than 30 mL/min - Use enoxaparin instead&lt;br&gt;Enoxaparin is contraindicated if eGFR is less than 15 mL/min&lt;br&gt;&amp;nbsp;&lt;br&gt;Please check previous administration to determine timing of next dose&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Fondaparinux OR Enoxaparin OR Heparin&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;enoxaparin (Noromby syringe/Redesca vial) injection (adult); 1 mg/kg/dose, subcutaneous, every 12 hours&apos;]/activities[at0001]"><items><item><key>CKT.Content Details</key><value>&lt;p&gt;&amp;nbsp;Please check previous administration to determine timing of next dose. Review dose after 72 hours&lt;/p&gt;</value></item></items></annotations><annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.orderable_section.v1 and name/value=&apos;Fondaparinux OR Enoxaparin OR Heparin&apos;]/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value=&apos;enoxaparin (Noromby syringe/Redesca vial) injection (adult); 0.75 mg/kg/dose, subcutaneous, every 12 hours&apos;]/activities[at0001]"><items><item><key>CKT.Content Details</key><value>&lt;p&gt;&amp;nbsp;Please check previous administration to determine timing of next dose. Review dose after 72 hours&lt;/p&gt;</value></item></items></annotations><definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="NSTEMI with possible PCI reperfusion"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.orderable_section.v1" concept_name="Orderable Section" max="1" path="/items" name="Ticagrelor OR Clopidogrel"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.orderable_section.v1" concept_name="Orderable Section" max="1" path="/items" name="ticagrelor (BRILINTA) 180 mg PO loading dose followed by 90 mg PO BID (preferred unless patient has history of intracerebral hemorrhage)"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="ef1367c5-ab42-49d9-a8b2-f4643cb92b72" concept_name="PHARM ticagrelor Tablet Order" max="1" path="/items" name="ticagrelor tablet; 180 mg, oral, once"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="ef1367c5-ab42-49d9-a8b2-f4643cb92b72" concept_name="PHARM ticagrelor Tablet Order" max="1" path="/items" name="ticagrelor tablet; 90 mg, oral, 2 times per day, First dose tomorrow"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/></Item><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="OR"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.orderable_section.v1" concept_name="Orderable Section" max="1" path="/items" name="clopidogrel (PLAVIX) 300 mg loading dose followed by 75 mg daily (select if ticagrelor cannot be used or if oral anticoagulation is also being used)"><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="948a4668-a1c3-4b7a-87d8-4a6a8c4e3c81" concept_name="PHARM clopidogrel Tablet Order" max="1" path="/items" name="clopidogrel tablet; 300 mg, oral, once"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="And"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="948a4668-a1c3-4b7a-87d8-4a6a8c4e3c81" concept_name="PHARM clopidogrel Tablet Order" max="1" path="/items" name="clopidogrel tablet; 75 mg, oral, daily, First dose tomorrow"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/></Item><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/></Item><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.orderable_section.v1" concept_name="Orderable Section" max="1" path="/items" name="Fondaparinux OR Enoxaparin OR Heparin"><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="df304555-4c58-4b0b-a80f-b7ef26442e72" concept_name="PHARM fondaparinux injection Order" max="1" path="/items" name="fondaparinux injection; 2.5 mg, subcutaneous, daily"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="OR"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="8c50ffc8-0dbe-4b6c-a856-5e03ab6eb2fe" concept_name="PHARM enoxaparin injection Order" max="1" path="/items" name="enoxaparin (Noromby syringe/Redesca vial) injection (adult); 1 mg/kg/dose, subcutaneous, every 12 hours"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="OR #1"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="8c50ffc8-0dbe-4b6c-a856-5e03ab6eb2fe" concept_name="PHARM enoxaparin injection Order" max="1" path="/items" name="enoxaparin (Noromby syringe/Redesca vial) injection (adult); 0.75 mg/kg/dose, subcutaneous, every 12 hours"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="OR #2"/><Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" template_id="57e4a27c-ac06-49fd-b52c-df497138f9a8" concept_name="Heparin for Cardiology Order Group" max="1" path="/items" name="Heparin Protocol for VTE Treatment"/><Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items"/></Item></definition><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.datetimeorderquestion.v1"><digest id="MD5-CAM-1.0.1">37AE50193A7EA542A4F219FF051EE95B</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.booleanorderquestion.v1"><digest id="MD5-CAM-1.0.1">56B5A2F2979B94F83C97E66B46679692</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1"><digest id="MD5-CAM-1.0.1">AD8DFB192E67715F0D9E11E95E674AD0</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.orderable_section.v1"><digest id="MD5-CAM-1.0.1">A89AC74BC8CAD3F0719579389C69006F</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1"><digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1"><digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.service_request_information.v1"><digest id="MD5-CAM-1.0.1">230A8D964017E1FD7AC82EBDEE0202A6</digest></integrity_checks><integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1"><digest id="MD5-CAM-1.0.1">A7EC4E4C870D8C3431B29F6514353416</digest></integrity_checks></template>
